Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
Surgical intervention · men with lower urinary tract symptoms secondary to benign prostatic obstruction
It is very uncertain whether combination therapy changes surgical intervention compared with alpha‐blockers (very low certainty).
1 finding from 1 review
Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy showed no clear difference in adverse events compared with anticholinergics (moderate certainty).
1 finding from 1 review
AUR · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy showed no clear difference in AUR compared with anticholinergics (low certainty).
1 finding from 1 review
Surgical intervention – not reported · men with lower urinary tract symptoms secondary to benign prostatic obstruction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
AUR · men with lower urinary tract symptoms secondary to benign prostatic obstruction
It is very uncertain whether combination therapy changes AUR compared with placebo (very low certainty).
1 finding from 1 review
Surgical intervention – not reported · men with lower urinary tract symptoms secondary to benign prostatic obstruction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy showed no clear difference in adverse events compared with alpha‐blockers (low certainty).
1 finding from 1 review
AUR · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy showed no clear difference in AUR compared with alpha‐blockers (low certainty).
1 finding from 1 review
Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens in combination with other phytotherapy showed no clear difference in urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher… compared with placebo or no intervention (low certainty).
1 finding from 1 review
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens in combination with other phytotherapy showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (low certainty).
1 finding from 1 review
Quality of life (Functional Assessment of Cancer Therapy‐prostate [FACT‐P; range 0 to 156; higher values = better quality of life]) measured at 12 months · men with metastatic, hormone‐sensitive prostate cancer
1 finding from 1 review
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib may leads to higher progression‐free survival (absolute effect size estimates based on… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (low certainty).
1 finding from 1 review